Pharmaceuticals, Biotechnology and Life Sciences
Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Cosentyx(TM) (secukinumab)…
REFRESH OPTIVE Gel Drops, a new aqueous gel expertly designed for patients who need or desire a more viscous artificial tear option to relieve their Dry Eye symptoms.
The percentage of Americans who reported using marijuana in the past year more than doubled between 2001-2002 and 2012-2013, and the increase in marijuana use disorder during that time was nearly as large.
Dechra has announced that on the closing date of its Takeover Offer to acquire the shares in Genera not owned by…
The Substance Abuse and Mental Health Services Administration (SAMHSA), in conjunction with the Centers for Medicare & Medicaid Services (CMS) and the Assistant Secretary of Planning and Evaluation (ASPE), today awarded a total of $22.9 million to support states throughout the nation in their efforts to improve behavioral health of their citizens by providing community-based mental and substance use disorder treatment.
Secretary of U.S. Department of Health & Human Services (HSS) Sylvia M. Burwell on Tuesday announced six new members to serve on the Advisory Council on Alzheimer’s Research, Care, and Services.
Allergan plc has completed the acquisition of AqueSys, Inc. a clinical-stage medical device company focused on developing ocular implants that…
“We were disappointed, but will soon have data from the Phase 3 study, OPUS 3,” said Flemming Ornskov, M.D., CEO, Shire.
Blood thinner (anticoagulant) can reduce the risk of a stroke by 50% to 60% for people who have atrial fibrillation.
The U.S. Food and Drug Administration on Friday granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa’s blood-thinning effects.